Blue Trust Inc. Sells 4,089 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Blue Trust Inc. reduced its position in Exact Sciences Co. (NASDAQ:EXAS) by 78.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,131 shares of the medical research company’s stock after selling 4,089 shares during the quarter. Blue Trust Inc.’s holdings in Exact Sciences were worth $64,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of EXAS. Asset Planning Inc acquired a new stake in Exact Sciences during the fourth quarter valued at approximately $40,000. Walkner Condon Financial Advisors LLC boosted its stake in Exact Sciences by 6.7% in the 4th quarter. Walkner Condon Financial Advisors LLC now owns 8,517 shares of the medical research company’s stock valued at $447,000 after buying an additional 534 shares in the last quarter. Vontobel Holding Ltd. grew its position in Exact Sciences by 47.0% in the fourth quarter. Vontobel Holding Ltd. now owns 5,833 shares of the medical research company’s stock valued at $328,000 after acquiring an additional 1,865 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Exact Sciences during the fourth quarter valued at $478,000. Finally, Kestra Private Wealth Services LLC boosted its stake in shares of Exact Sciences by 22.9% in the 4th quarter. Kestra Private Wealth Services LLC now owns 8,387 shares of the medical research company’s stock valued at $471,000 after purchasing an additional 1,564 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $51.28 on Tuesday. The stock has a 50-day moving average of $54.72 and a 200-day moving average of $60.00. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62. The stock has a market cap of $9.53 billion, a PE ratio of -9.21 and a beta of 1.24. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.23. The company had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. As a group, sell-side analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on EXAS shares. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Jefferies Financial Group lifted their target price on shares of Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Bank of America decreased their price target on Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Evercore ISI cut their price objective on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, BTIG Research increased their target price on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.24.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.